Please assess the completion status of the following clinical trial:

Trial Title: Randomized, Controlled Multicenter Trial of Vacuum Assisted Closure Therapy™ in Diabetic Foot Ulcers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Presence of a calcaneal, dorsal or plantar diabetic foot ulcer ≥ 2 cm2 in area after debridement. (If more than one ulcer is present, all wounds will be treated using the same method, but only one ulcer will be studied.)~* DFU equivalent to Stage 2 or greater, as defined by Wagner's Scale system (See Appendix E)~* Evidence of adequate perfusion by one of the following on the affected extremity,(within the past 60 days):Dorsum transcutaneous oxygen test (TcPO2) with results of ≥30 mmHg, or ABIs with results of ≥0.7 and ≤1.2 and toe pressures with results of ≥30 mmHg, or Doppler arterial waveforms, which are triphasic or biphasic at the ankle in the affected leg.~* Age ≥ 18 years of age~* HbA1c ≤ 12% (collected within the last 90 days.)~* Evidence of adequate nutrition by one of the following:~* Lab results reflecting Pre-Albumin \>16 mg/dl and Albumin level is \>3 g/dl (during the seven days prior to the study period), or a nutritional consult will be done and with appropriate supplementation started. Proper documentation on CRFs is needed.~Exclusion Criteria:~* Patients with recognized active Charcot abnormalities of the foot, as evidence by clinical symptoms that interfere with either randomized treatment group~* Ulcers resulting from electrical, chemical, or radiation burns, or venous insufficiency~* Untreated infection or cellulites at site of target ulcer~* Presence of untreated osteomyelitis~* Collagen vascular disease~* Malignancy in the ulcer~* Presence of necrotic tissue~* Uncontrolled hyperglycemia~* Concomitant medications that include (washout period of 30 days for corticosteroids, immunosuppressive medications, or chemotherapy)~* Open amputations~* Prior V.A.C. therapy within 30 days.~* Current or prior normothermic (Warm-UP®) or HBO therapy within 30 days.~* Current or prior treatment with recombinant or autologous growth factor products within the past 30 days. (Examples: Regranex or Procuren)~* Current or prior treatment with skin or dermal substitutes and dressings (Examples: Apligraft, Dermagraft, or Integra) with living cells capable of producing growth factors (Example: Oasis) within the past 30 days.~* Current use of any enzymatic debridment agent (Example: Acuzyme /Panafil) during the active treatment phase of the study~* Pregnant or nursing mothers.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VAC Therapy (Type: EXPERIMENTAL): Treatment of Diabetic Foot Ulcers with VAC Therapy
- Moist Wound Therapy (Type: ACTIVE_COMPARATOR): Moist Wound Therapy (standard of care)

Based on this trial design, predict the completion outcome and termination type (if applicable).